Nkarta Inc. (NKTX)
2.35
-0.07 (-2.89%)
At close: Jan 28, 2025, 2:40 PM
undefined% (undefined)
| Bid | 2.35 |
| Market Cap | 166.19M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -1.29 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.36 |
| Volume | 546,496 |
| Avg. Volume (20D) | 1,618,227 |
| Open | 2.40 |
| Previous Close | 2.42 |
| Day's Range | 2.27 - 2.43 |
| 52-Week Range | 2.08 - 16.24 |
| Beta | undefined |
About NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 159
Stock Exchange NASDAQ
Ticker Symbol NKTX
Website https://www.nkartatx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 579.41% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
5 months ago
+3.22%
Nkarta shares are trading higher after the company...
Unlock content with
Pro Subscription
6 months ago
+13.96%
Nkarta shares are trading higher after the company appointed Nadir Mahmood as President.
